BioMed Research International
Volume 2017 (2017), Article ID 5245021, 15 pages
https://doi.org/10.1155/2017/5245021

Review Article

Emerging and Neglected Infectious Diseases: Insights, Advances, and Challenges

Nicholas Israel Nii-Trebi

Department of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana

Correspondence should be addressed to Nicholas Israel Nii-Trebi; nntrebi@chs.edu.gh

Received 13 August 2016; Revised 5 January 2017; Accepted 16 January 2017; Published 13 February 2017

Academic Editor: André Talvani

Copyright © 2017 Nicholas Israel Nii-Trebi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Infectious diseases are a significant burden on public health and economic stability of societies all over the world. They have for centuries been among the leading causes of death and disability and presented growing challenges to health security and human progress. The threat posed by infectious diseases is further deepened by the continued emergence of new, unrecognized, and old infectious disease epidemics of global impact. Over the past three and half decades at least 30 new infectious agents affecting humans have emerged, most of which are zoonotic and their origins have been shown to correlate significantly with socioeconomic, environmental, and ecological factors. As these factors continue to increase, putting people in increased contact with the disease causing pathogens, there is concern that infectious diseases may continue to present a formidable challenge. Constant awareness and pursuance of effective strategies for controlling infectious diseases and disease emergence thus remain crucial. This review presents current updates on emerging and neglected infectious diseases and highlights the scope, dynamics, and advances in infectious disease management with particular focus on WHO top priority emerging infectious diseases (EIDs) and neglected tropical infectious diseases.

1. Introduction

A “disease” is any condition that impairs the normal function of a body organ and/or system, of the psyche, or of the organism as a whole, which is associated with specific signs and symptoms. Factors that lead to organs and/or systems function impairment may be intrinsic or extrinsic. Intrinsic factors arise from within the host and may be due to the genetic features of an organism or any disorder within the host that interferes with normal functional processes of a body organ and/or system. An example is the genetic disease, sickle cell anaemia, characterized by pain leading to organ damage due to defect in haemoglobin of the red blood cell, which occurs as a result of change of a single base, thymine, to adenine in a gene responsible for encoding one of the protein chains of haemoglobin. Extrinsic factors are those that access the host’s system when the host contacts an agent from outside. An example is the bite of a mosquito of Anopheles species that transmits the Plasmodium falciparum parasite, which causes malaria. A disease that occurs through the invasion of a host by a foreign agent whose activities harm or impair the normal functioning of the host’s organs and/or systems is referred to as infectious disease [1–3].

Infectious diseases are generally caused by microorganisms. They derive their importance from the type and extent of damage their causative agents inflict on organs and/or systems when they gain entry into a host. Entry into host is mostly by routes such as the mouth, eyes, genital openings, nose, and the skin. Damage to tissues mainly results from the growth and metabolic processes of infectious agents intracellular or within body fluids, with the production and release of toxins or enzymes that interfere with the normal functions of organs and/or systems [4]. These products may be distributed and cause damage in other organs and/or systems or function such that the pathogen consequently invades more organs and/or systems.

Naturally the host’s elaborate defence mechanism, immune system, fights infectious agents and eliminates them. Infectious disease results or emerges in instances when the immune system fails to eliminate pathogenic infectious agents. Thus, all infectious diseases emerge at some point in time in a given population and in a given context or environment. By understanding the dynamics of disease and the means of contracting it, methods of fighting, preventing, and controlling are developed [2, 5, 6]. However, some pathogens, after apparent elimination and a period of dormancy, are able to acquire properties that enable them to reinfect their original or new hosts, usually in increasingly alarming proportions.

Understanding how once dominant diseases are reappearing is critical to controlling the damage they cause. The world is constantly faced with challenges from infectious diseases, some of which, though having pandemic potential, either receive less attention or are neglected. There is a need for constant awareness of infectious diseases and advances in control efforts to help engender appropriate public health responses [7, 8].

2. Emerging Infectious Diseases

The phenomenon of disease emergence was historically long understood by scientists. This was well expressed by Charles Nicolle, then director of the Institute Pasteur de Tunis, in a talk he gave in 1920 on “Life and Death of Infectious Diseases” to highlight the potential threat that infectious diseases represent [2, 10]. The concept of emerging diseases appeared over time, but began to receive attention in the late 1960s to mid-1970s with the sudden appearance of the viral haemorrhagic fevers such as Crimean-Congo haemorrhagic fever, Lassa fever, and Ebola fever. EID received greater attention with the appearance of other severe syndromes in the 1980s during which unusually big epidemics including HIV/AIDS occurred.

The terms “emerging and reemerging diseases” were formally given by Joshua Lederberg, Robert B. Shope, and Mary Wilson in 1987. The term is used in reference to diseases of infectious origin and whose incidence in humans has either increased within the past two decades or threatens to increase in the near future [11]. A 1992 report by the Institute of Medicine (IOM) on emerging infections, which underscored the microbial threats to health in the United States [1, 2, 12, 13], provided the impetus for current widespread attention on emerging and reemerging infectious diseases. This formal designation seemed to have drawn greater attention and placed the issue of emerging diseases high on the agenda of national and international health programs and has formed a key part of various organizational, institutional, and departmental research focus. The field of emerging disease exploration was strengthened by the creation of “special pathogens branch,” which is a special force on emerging diseases by the WHO at the Centre for Disease Control and Prevention (CDC) in Atlanta, Georgia, USA [14, 15]. The main objective was to spearhead research and related activities aimed at understanding the emergence of new infectious diseases and their reappearance in new populations after a long period of silence and find ways to prevent or control them.

EID thus falls under two major categories—newly emerging and reemerging infectious diseases. Newly emerging infections refer to diseases that have been discovered in the human host or a population for the first time; reemerging infectious diseases can be defined as infectious diseases that reappear, usually in more pathogenic form and in rapidly increasing incidence or new geographic locations after apparent control or eradication [6, 7]. Emerging infections (EIs) have featured prominently in the course of human history; they have caused inestimable harm to humanity [16]. They represent a continued threat to humanity and therefore deserve awareness and preparedness at all times.

3. Major Causes of Infectious Disease Emergence

Emergence and reemergence of infectious diseases occur over time. Prior to causing an epidemic, infectious disease agents go through various stages of adaptation to access or acquire pathogenic characteristics in a new host [17]. Specific processes such as gene mutation, genetic recombination, or reassortment as well as factors that compel microbial agents to change reservoir hosts constitute opportunities for infectious agents to evolve, adapt to new hosts in new ecological niches, and spread easily [18, 19]. A number of factors contribute to this adaptation and consequent disease emergence. The complex interactions between infectious agents, hosts, and the environment are key.

Specifically, factors affecting the environment include depletion of forests, expansion and modernization of agricultural practices, and natural disasters such as floods. These potentially lead to changes in microbial ecological niches and fuel microbial adaptation to human host [20, 21]. Sociodemographic factors such as increase in population density, falling living standards, decline of infrastructure, human travel, conflicts and social instability, and killing of wild animals for meat all lead to increase in host-microbe contact, which facilitate infections in humans [22–25]. There are also some pathogens whose emergence is as a result of deliberate human action. These are those employed as biological weapons for destruction and so their emergence is “deliberate.”

Besides host and environmental factors, changes or mutation in the genome of a pathogen, which occurs as a result of exposure to chemicals and antimicrobial agents (e.g., antibiotic), may lead to gene damage [26] and emergence of drug resistant pathogen variants that could cause new disease [18]. Thus, human, microbial, and environmental factors constitute major causes of infectious disease emergence and the virulence or pathogenic potential depends on a complex combination of these factors [27]. However, generally, emerging infectious diseases caused by viral pathogens are responsible for the greatest proportion of the EID threat, having caused about two-thirds of the infectious disease burden and usually characterized by very high epidemics. Examples are Filoviruses, Ebola, and Marburg [28, 29].

4. The Emerging Infectious Disease Burden

Infectious diseases (IDs) occupy a prominent position in world history owing to the highly significant burden they present to human survival and development. They constitute a significant proportion of all human diseases known. At least 25% of about 60 million deaths that occur worldwide each year are estimated to be due to infectious diseases [30, 31]. Neglected IDs claim the lives of more than half a million people every year and have rendered at least 1 billion people chronically infected [32]. The scourge of emerging IDs is also well known since ancient times.

There are myriad examples that underscore the gravity of the impact infectious diseases have had on humans. In the Middle Ages the Black Death (1348–1350) killed 30%–60% of Europe’s population. In the 18th century, smallpox killed an estimated 400,000 Europeans each year and rapidly decimated and weakened native populations in the Americas and Australia and, in the 20th century, it was responsible for an estimated 300–500 million deaths, prior to its final eradication in the late 1970s [33–35]. Like smallpox, measles has been a scourge for centuries, afflicting millions of people, causing massive destruction to native populations especially in the Americas and Europe over the years. In 1989–91, there were 55,000 cases in a measles outbreak in the US, which led to 11,000 hospitalizations and 123 deaths. In 2000 measles was declared eradicated in the US; however, it continues to circulate in various parts of the world, having caused as many as 114 900 deaths globally in 2014 [36–38]. Even with the availability of a safe and cost-effective vaccine, measles remains one of the leading causes of death among young children. Furthermore, diarrhoeal disease, mainly caused by a variety of bacterial, viral, and parasitic organisms, is the second leading cause of death in children under five years old and is responsible for killing around 760 000 children every year (Ref: WHO, diarrhoeal disease), while, in older children, pneumonia, diarrhoea, and malaria represent the leading causes of death due to infectious disorders.

Influenza is another major infectious disease the world has witnessed. No other infectious disease has ever claimed as many lives as the 1918-1919 Spanish Influenza epidemic, which killed as many as 40 million people worldwide. The 1918-1919 influenza pandemic killed more people than the World War I (the Great War); it killed more people in one year than in four years of the Black Death Bubonic Plague that occurred in 1347–1351 and more people than thirty-five years of the HIV/AIDS pandemic, which caused an estimated 35 million deaths at the end of 2015 [33, 39, 40]. It has been referred to as the most devastating epidemic recorded in world history and a global disaster [41]. Other devastating infectious diseases include haemorrhagic fevers and the 2014 Ebola disease outbreak, which recorded a total 28,638 cases with 11,316 deaths in ten countries worldwide [42–44]. A number of neglected infectious diseases can also be cited, for example, malaria and diarrhoeal diseases, which alone cause about three million deaths in children every year, and tuberculosis, African trypanosomiasis, echinococcosis, schistosomiasis, leishmaniasis, ascariasis, rabies, cysticercosis, and dengue (Table 3). All these cause various forms of disabilities and death especially in developing nations, afflicting more than one billion people and costing developing nations billions of dollars year after year, besides incalculable wounds inflicted on the sufferers [32, 45].

A number of psychological, emotional, and mental effects associate infectious diseases that worsen the plight of people living with an infectious disease [46, 47]. Some infectious diseases such as leprosy bring shame on those affected and make them shunned or maltreated by their communities. Sufferers tend to lose their freedom and worth. Furthermore, loss of capacity to work due to an infectious disease further increases poverty in adults, which consequently may affect children’s education [48]. Infectious diseases also affect cognitive development of children, leading to various social vices that ultimately add to the burden created by the disease and thereby consequently worsen poverty. Thus people in developing countries suffer heavily from the burden of ill health and death caused by infectious diseases, infants and children being the most affected [45, 49, 50].

5. Transmission

Infectious diseases arise upon contact with an infectious agent. Five major infectious agents have been recognized, namely, bacteria, viruses, fungi, protozoa, and helminths [7, 51]. Various factors can be identified that create opportunities for infectious agents to invade human hosts. These include global urbanization, increase in population density, poverty, social unrest, travel, land clearance, farming, hunting, keeping domestic pets, deforestation, climate change, and other human activities that destroy microbial habitat [22, 52]. For example, in 1987, a large West Africa RVF outbreak in both human and animal populations was attributed to change in the ecological conditions and animal-humans interactions, caused by flooding in the lower Senegal River area due to construction work on the Senegal River [53].

Human engagement in activities that interfere with ecological and environmental conditions continues, thereby increasing the risk of contact with new pathogens. These pathogens are mostly transmitted though intermediate animal hosts such as rodents [1, 54], which gain increased contact with humans as a result of environmental and human behavioural factors (Table 1). Pathogens may be shared through animal urine and droppings which may be aerosolized and infect susceptible vertebrates including humans. Examples are seen in Lassa fever, Hantavirus Pulmonary Syndrome, and the Nipah virus encephalitis (Table 2), whose viral pathogens have been found to coevolve with specific rodent species [55].

Table 1: Some past emerging infectious disease epidemics and probable factors for outbreak.

Year
Emerging disease
Pathogenic agent
Main probable factor

1958
Argentine haemorrhagic fever
ArenavirusJunin virus
Changes in agricultural practices of corn harvest (maize mechanization)

1981
Acquired immunodeficiency syndrome (AIDS)
Human immunodeficiency virus
Sexual contact/exposure to blood or tissues of an infected person

1959
Bolivian haemorrhagic fever (BHF)
ArenavirusMachupo virus
Population increase of rats gathering food

1983
Crimean-Congo haemorrhagic fever
CCHF virus
Ecological changes favouring increased human exposure to ticks of sheep and small wild animals

1996
Haemorrhagic colitis
Escherichia coli O157:H7
Ingestion of contaminated food, undercooked beef, and raw milk

1976
Malaria
Plasmodium falciparum
Human behaviour/rainfall and drainage problems/mosquito breeding/neglect of eradication policy, economics, and growing interchange of populations

1993
Hantavirus pulmonary syndrome (HPS)
HantavirusSin Nombre virus
Human invasion of virus ecological niche; close contact with infected rodent natural reservoir; inhalation of infectious aerosolized rodent faces and urine

1997
Highly pathogenic avian influenza (HPAI)
H5N1 virus
Animal-animal influenza virus gene reassortment; emergence of H5N1 avian influenza, extensive chicken farming

1889, 1890, 1918, 1957
Pandemic Influenza
Paramyxovirus influenza A
Animal-human virus reassortment and antigenic shift

1969
Lassa fever
Arenavirus Lassa virus
Hospital exposure to index case—rodent exposure

1956
Marburg disease
Filovirus Marburg virus
Trade (and use of wild imported monkeys); use of animal organs for specific purpose

2003
Severe acute respiratory syndrome (SARS)
SARS Coronavirus
Hunting and feeding on infected wild animals (viverrids)

1987
Rift Valley fever (RVF)
Bunyavirus RVF virus
Dramatic increase in mosquito vector breeding sites (by dam filling); weather (rainfall) and cattle migration (guided by artificial water holes)

1976
Ebola haemorrhagic fever
Filovirus Ebola virus
Rainforest penetration by humans/close contact with infected game (hunting) or with host reservoirs (bats)/infected biological products/nosocomial/needle spread

1953
Dengue haemorrhagic fever (DHF)
Dengue viruses 1, 2, 3, and 4
Increasing human population density in cities in a way that favours vector breeding sites (water storage), for example, Aedes aegypti

Note: adapted from “Encyclopedia of Infectious Diseases-Modern Methodologies” [2].

Table 2: Top priority emerging infectious diseases.

Emerging disease
Crimean-Congo haemorrhagic fever
Ebola virus disease & Marburg haemorrhagic fever
Middle East Respiratory Syndrome & SARS
Lassa Fever
Nipah
Rift Valley Fever

Year of (re)emergence
(1) 12th Century,
(2) 1944-45 & 1967
Ebola: 1976
Marburg: 1967
MERS: 2012
SARS: 2002
Isolated in 1969
1998-1999
In livestock: 1910s
In humans: 1931 (all in Kenya)

Causative organism
Nairovirus (CCHF virus)
EVD: Ebola virus
MHF: Marburg virus
MERS: MERS-CoV
Lassa virus
Nipah virus (NiV)
Rift Valley Fever (RVF) virus

Type/class of organism
Virus (Bunyaviridae)
Virus (Filoviridae)
Virus (Coronaviridae)
Virus (Arenaviridae)
Virus (Paramyxoviridae)
Virus (Bunyaviridae)

Vector/animal host
Hyalomma tick,
Domestic animals
Fruit bats species
EVD: Pteropodidae
MHF: Rousettus aegypti
Not well known; camel is implicated as reservoir host
Mastomys rats
Fruit bats of genus Pteropus
(1) Mosquito species, mainly Aedes sp.
(2) Domestic remnant

Epidemiology
Fatality rate of 10–40%, at least 140 outbreaks & 5000 cases since 1967
EVD: about 50% fatality. At least 31,076 cases with 12,922 deaths since 1976
MHF: case fatality rate is up to 88%
MERS: case fatality approx. 36%; severe in people with weakened immune systems, with chronic diseases
At least 100,000 cases annually in the endemic regions of West Africa with case fatality rates of 5–10%
At least 477 people infected, 252 killed since 1998; case fatality rate of 40–70%
Commonly affects livestock, causing disease, abortion, and death in thousands of domesticated animals

Populations at risk
Endemic in Africa, the Balkans, the Middle East, and Asia
EBV: Africa
MHF: Frankfurt in Germany; Belgrade and Africa
MERS: people with chronic disease. Countries include Egypt, Oman, Qatar, and Saudi Arabia
Endemic in West Africa
Southeast Asia region
Africa and Arabian Peninsula

Mode of transmission
(1) Tick bites
(2) Zoonotic: contact with infected animal blood and with secretions or body fluids of infected persons
EBV: contact with blood, secretions, and body fluids/organs of infected (a) nonhuman primates and (b) humans
MHF: mainly human-to-human
MERS is zoonotic: no human-to-human transmission; origin and exact route are unknown
Zoonotic: (1) exposure to urine or faeces of infected Mastomys rats
(2) Direct contact with body fluids of infected person
(1) Contact with excretion and secretion of infected bats
(2) Direct contact with infected pigs
Zoonotic and Epizootic:
Bite of infected mosquitoes (in humans and animals)

Clinical presentations
Nonspecific: high fever, myalgia, headache, nausea, abdominal pain, and nonbloody diarrhoea
Clinically similar: fever, severe headache, diarrhoea, lethargy, and so on; impaired kidney function, internal /external bleeding, and nervous system problems (MHF)
Ranges from no symptoms to death. Generally fever, cough, and shortness of breath; pneumonia, gastrointestinal problems, and respiratory failure
About 80% of infections are asymptomatic. Symptoms are variable: fever, cough, malaise; pains, fluid in the lung cavity, facial swelling, bleeding, and more
(1) Barking pig syndrome (in pigs)
(2) In humans: fever, muscle pain; brain inflammation leading to coma
Humans: include fever, muscle/joint pain; eye disease, meningoencephalitis, and haemorrhagic fever
Animals: mortality and abortion

Pathogenesis
Not well understood
Not well understood
Not well understood
Not well understood
Not well understood
Not well understood

Diagnosis
(1) Virus isolation by cell culture
(2) Viral genome detection (RT-PCR)
(3) Serology (ELISA)
(1) Virus isolation by cell culture
(2) Viral genome detection (RT-PCR)
(3) Serology (e.g., ELISA)
(1) Mainly by molecular detection (RT-PCR)
(2) Also serology (ELISA)
Only in reference labs: isolation by cell culture, viral genome detection (RT-PCR), and serology (ELISA & neutralization)
(1) Virus isolation
(2) Histopathology
(3) RT-PCR
(4) Serology (ELISA, neutralization)
(1) Isolation by cell culture
(2) Viral genome detection (RT-PCR)
(3) Serology (ELISA)

Treatment
No vaccine available:
(1) General supportive care management
(2) Ribavirin antiviral
No vaccine or specific antiviral treatment. General supportive care management
MERS: no vaccine or specific treatment. General supportive care management
No vaccine yet
(1) Early supportive care
(2) Ribavirin antiviral therapy seems effective
No vaccine available
(1) Symptoms management;
(2) Ribavirin antiviral treatment
No specific treatment; generally supportive therapy

Prevention
Minimize tick burden in livestock, minimize human contact with vertebrate hosts
Awareness
EVD: good hygiene; avoid contact with blood and body fluids
MHF: protect pigs from fruit bats contact
MERS: general hygiene measures in contacting camels/other animals; avoid consumption of raw or undercooked animal products
(1) Good hygiene—in community, homes
(2) Standard infection prevention and control measures in healthcare and lab settings
Avoid contact with infected secretions, excretions, blood, or tissues of infected pigs and bats
(1) Animal vaccination
(2) Protection against vector bites
(3) Animal health surveillance

Note. Source of list: http://www.who.int/medicines/ebola-treatment/WHO-list-of-top-emerging-diseases/en/ [9].

MERS: Middle East Respiratory Syndrome; SARS: Severe Acute Respiratory Syndrome.

Table 3: Major neglected tropical diseases.

Disease
Causative agent
Transmission
Pathogenesis
Affected populations
Treatment and management
Prevention/public health response

 Buruli ulcer
Mycobacterium ulcerans (Bacterium)
Mode unknown
Destruction of skin & soft tissues, leading to ulcer
Poor rural communities; more in Africa, 33 countries
Rifampicin, streptomycin/amikacin, or surgery
Early detection and antibiotic treatment

Chagas disease
Trypanosoma cruzi (protozoan parasite)
Vector-borne
Cardiac or mixed alterations in chronic infection
~8 M people infected worldwide, mostly Latin America
Curable with benznidazole and nifurtimox
Vector (triatomine bug) control

Dengue and chikungunya
Dengue virus sp.: DENV 1, DENV 2, DENV 3 & DENV 4 (Flaviviruses)
Dengue & chikungunya: mosquito sp. (Aedes aegypti & Ae. albopictus)
Fatal: plasma leaking, bleeding, and organ impairment
Worldwide, ~100 countries; 50–100 mil infections/year. Esp. Asia & Latin America
Dengue: vaccine available; chikungunya: no vaccine
Control of mosquito vectors

Dracunculiasis (Guinea worm disease)
Dracunculus medinensis (Nematode parasite)
Drinking water containing parasite-infected water-fleas (Cyclops)
Rarely fatal
Leads to oedema and ulcer, usually of the feet
22 cases in 4 African countries in 2015
No vaccine available yet
Improved drinking water sources. Near eradication

Echinococcosis
E. granulosus and
E. multilocularis (Echinococcus parasites)
Through faeces of dogs, foxes & other carnivores
Involves liver and other organs. Progressive and fatal if untreated
>I M people worldwide affected at any one time
Expensive and complicated to treat
Complex
Regular deworming of domestic carnivores helps

Endemic treponematoses (Yaws)
T. Pallidum subspecies pertenue (bacterium)
Person-to-person (nonsexual) with infected fluid
Disfigurement of the nose and bones; hyperkeratosis
Africa, Asia, Latin America, and the Pacific
Azithromycin
Benzathine penicillin
No vaccine: early diagnosis and targeted treatment

Foodborne trematodiases
Trematode parasite sp. Clonorchis, Opisthorchis, Fasciola, and Paragonimus
Zoonotic: consumption of raw/poorly cooked food
Organ-specific, reflects adult worm final location
>70 countries worldwide, mainly East Asia and South America
Use of anthelminthic medicines
Reduce infection risk; control associated morbidity

Human African trypanosomiasis (sleeping sickness)
Trypanosoma parasite sp.
T. brucei gambiense (98%)
T. brucei rhodesiense (2%)
By bites of infected tsetse fly (of Glossina genus)
Affects central nervous system, causing neurological (and sleep) disorders
Occurs in 36 sub-Saharan Africa countries (>70% of cases occur in DR Congo)
Drugs available. Depends on disease stage and parasite species
Free antitrypanosome medicines provided by WHO; efforts at elimination

Leishmaniasis
Protozoan Leishmania parasites (over 20 species)
Bite of infected female phlebotomine sandflies
Infection rarely leads to disease development
Worldwide. Risk increased by poverty
Complex; depends on several factors
Complex; combination of intervention strategies

Leprosy (Hansen disease)
Mycobacterium leprae (bacterium)
By air (from nose & mouth) through close contact
Damage of peripheral nerves leading to paralysis
Southeast Asia Region
Multidrug (Dapsone, rifampicin & clofazimine)
Early diagnosis and treatment to avert disability

Lymphatic filariasis (elephantiasis)
Filarioidea nematodes: Wuchereria bancrofti, Brugia malayi, and B. timori
By mosquito sp. (Culex, Anopheles, and Aedes)
Invade lymphatic system; disrupt immune system
WHO Southeast Asia & Africa; >120 M people
Albendazole + ivermectin/diethylcarbamazine citrate
Morbidity management; mass drug administration

Onchocerciasis (river blindness)
Onchocerca volvulus (parasite)
Bite of blackfly (Simulium damnosum sp. mainly)
Parasites migrate throughout the body, casing a variety of symptoms
36 countries: Africa, Arabian peninsula & Americas
Ivermectin (manufactured Merck & Co, free)
Yearly ivermectin administration to affected populations

Rabies
Rabies virus
Bites/scratches of affected domestic/wild animals
Affects central nervous system, leads to death
All continents but Antarctica. Mostly in Asia & Africa
Postexposure prophylaxis (with vaccine course)
Preventive immunization of people; vaccinating dogs

Schistosomiasis (Bilharzia)
Schistosoma parasite sp.: S. haematobium, S. mansoni, and S. japonicum
Contact with infested fresh water bodies
Live in blood vessels, body tissues & damage organs
At least 90% of estimated cases are in Africa
Drug available: Praziquantel therapy
Good water/sanitation, snail control; preventive therapy

Soil-transmitted helminthiases
Helminth parasite species Ascaris lumbricoides, Trichuris trichiura, Necator americanus & A. duodenale
Parasite eggs in human faeces-contaminated soil
Intestinal damage and blood loss. Rarely fatal
Worldwide: esp. sub-Saharan Africa, the Americas, China, and East Asia. ~2 billion people
Medicines available: Albendazole and Mebendazole
Deworming people at risk, improved sanitation, education

Taeniasis/ cysticercosis
Taenia (tapeworm) parasites
T. solium (pork tapeworm)T. saginata (beef tapeworm)
Ingestion of larval cysts through contaminated food (pork or beef) or water
Intestinal; central nervous system attack. Can be fatal
Africa, Asia, and Latin America
Drug available: Praziquantel and niclosamide
Veterinary, human health, and environmental approach

 Trachoma
Chlamydia trachomatis (bacterium)
Eye-seeking flies, poor water and sanitation
Leading infectious cause of blindness globally
51 countries, 1.2 M people blind, 232 M at risk
Surgery, antibiotics, and facial cleanliness
Environmental improvement; target: elimination by 2020

Note. M: million.

Source of list: http://www.who.int/neglected_diseases/diseases/en/.

The emergence and transmission of an infectious disease pathogen in humans, as exemplified in Table 1, primarily follows a pathway that involves a reservoir host, which may employ a vector or secondary host to contact a native host such as human or animal index case. Specific mechanisms are required for the emergence and transmission process and these mainly include a certain level of host behaviour, pathogen changes, and environmental factors as well as contact and/or spillover between reservoir specimens and the native host [2, 17]. While reservoir and secondary hosts favour transmission to other species including wild animals, domestic animals, and humans, changes in susceptible host behaviour due to population density and biodiversity favour sustained pathogen spread. Epidemics in pandemic proportions emerge due to sustained intersusceptible host or secondary host transmission of pathogens; thus failure to initiate cross-species infection or generate secondary infections interrupts the emergence process [4].

Some infectious agents that have adapted to nonhuman hosts can be transmitted to humans but not from human to human, resulting in what is termed a “dead end” transmission. Thus, most of the important EIs, unlike HIV, are mainly zoonoses, in that they are infections in animals that are transmitted to humans. Others are vector-borne diseases and so require arthropod vector for their transmission from one vertebrate to another. HIV transmission on the other hand is mainly from human to human by heterosexual means. Socioeconomic factors are responsible for bulk of the infections which have been recorded in the developing world [56–58].

In most cases, a combination of risk factors accounts for infectious disease emergence and/or outbreak of epidemic such as the 2014 West Africa Ebola Virus Disease (EVD) outbreak. The EVD outbreak originated at Meliandou, located in Gueckedou District, Guinea (on 26 December 2013 but was not identified as Ebola until 21 March 2014). Meliandou is known as the Forest Region [59, 60] and it is close to an area where the three countries, Guinea, Sierra Leone, and Liberia, share common borders. Much of the surrounding forest area has, however, been destroyed through foreign mining and timber operations. There is freedom of intercountry movement for commercial, social, and cultural activities. There is some evidence suggesting that the destruction of the forest (estimated at more than 80%) brought potentially infected wild animals, including the bat species, which is thought to be the natural reservoir of the virus, into closer contact with human settlements [61, 62]. Epidemiological studies showed that apart from a few cases linked to an original animal reservoir-to-human transmission, all subsequent cases could be traced back to a single transmission chain involving an index case, an 18-month-old boy. With the exception of those involving foreign healthcare workers, most of the cases were relatives or members of a common social cycle. Extreme poverty, a weakened healthcare system and other government institutions as a consequence of years of civil war, lack of basic infrastructure, poor education standards, dysfunctional societal structures, and certain local customs such as washing the body after death before burial [63, 64] all contributed to the emergence of the outbreak and failure to control the epidemic. This exemplifies the complex and interrelated nature of factors involved in infectious disease emergence.

6. Current Top Priority Infectious Diseases

As part of a global strategy and preparedness plan (Blueprint) for rapid activation of research and development (R&D) activities during and to prevent epidemics, the WHO convened a meeting of a group of scientists and public health experts in Geneva on 8-9 December, 2015, to prepare a process for prioritization of severe emerging disease pathogens with the greatest risk of epidemic or pandemic potential [65, 66]. The prioritization was based on a number of factors bordering on the likelihood to cause severe outbreaks necessitating public health emergency in the near future and inadequacy or nonavailability of medical countermeasures. Against this background seven diseases prioritized for urgent action are Crimean-Congo haemorrhagic fever, Filovirus diseases (Ebola virus disease and Marburg), highly pathogenic emerging Coronaviruses relevant to humans (MERS Co-V and SARS), Lassa fever, Nipah, Rift Valley Fever, and a “new disease.” The seventh disease, denoted as “a new disease” thus refers to any hitherto unknown disease that may emerge and require urgent action to contain or prevent epidemics. Table 2 gives essential descriptions of the known priority pathogens [67].

Also listed as serious, necessitating action by WHO to help control them as soon as possible, were these three diseases: chikungunya, Severe Fever with Thrombocytopenia Syndrome, and Zika. First discovered in 1947, evidence of vector-borne Zika virus transmission has been reported in 65 countries and territories since 2015; it has thus been declared a health emergency by WHO [68]. Diseases such as HIV/AIDS, tuberculosis, malaria, avian influenza, and dengue, which also have epidemic potential, were not included in the top priority list of pathogens requiring major control and research networks because there are appreciable funding and mechanisms for improved intervention well in place for these disease pathogens. The Flaviviruses, dengue and chikungunya, are however on the WHO current list of neglected tropical diseases (NTDs) [9, 69]. Details about 16 current most neglected tropical diseases are given in Table 3.

7. Public Health Response

EIDs and neglected infectious diseases are both driven to a large extent by human, environmental, and ecological factors. NTDs, however, thrive and persist more under conditions of poverty. People affected by neglected tropical diseases are often of low status in terms of public health priorities and lack strong political voice [70, 71]. A reasonable public health response towards addressing infectious disease problem in general therefore aims at addressing the fundamental factors that promote the occurrence and persistence of these diseases, while embarking on appropriate control measures. WHO therefore supports advocacy and awareness and pathogenesis studies and development and deployment of diagnostic tools and therapeutic drugs and vaccines as the pillars of public health response [72–74].

The international community has recognized the need to galvanize investment to enhance preparation and response to infectious disease threats. Recognizing the existence of many tropical, poverty-related diseases, including neglected tropical diseases, affecting the same populations, the 66th World Health Assembly of the WHO in May 2013 adopted a resolution (WHA66.12), which called on Member States to intensify and integrate measures and pursue investments aimed at improving the health and social well-being of affected populations [75]. The adoption by the WHO of a novel research and development plan, the Blueprint, for rapid activation of activities to address future epidemics is another positive step towards preparedness. Furthermore, there are a number of other important initiatives by national and international bodies, organizations, and foundations with vigorous research and financial commitments towards addressing infectious disease threats [76, 77].

Apparently, NTDs were not listed among the United Nation’s Millenium Development Goals (MDGs). Fortunately, NTDs were covered through the Bill & Melinda Gates Foundation funding for research and public health projects related to global health [78]. Further initiatives include the founding of the Global Network of various organizations for NTDs in 2006, also with financial support from the Gates Foundation; the adoption of the historic London Declaration on Neglected Tropical Diseases, was made, in early 2012, at a meeting of major stakeholders including the World Bank, the Bill & Melinda Gates Foundation, governments, pharmaceutical companies, and other organizations, as well as the WHO commitment to “Accelerating Work to Overcome the Global Impact of Neglected Tropical Diseases.” At least US$ 785 million pledge was made by members towards attainment of the goals of the London declaration, which were to accelerate research and development of new drugs for NTDs and to expand effective drug distribution [79, 80]. This is unprecedented.

In terms of disease management, preventive chemotherapy, vector control, and pesticide management and provision of safe drinking water, basic sanitation and hygiene, and education; veterinary public health services are some of the public health strategies employed by the WHO for the control, elimination, and eradication of NTDs [81, 82]. Preventive chemotherapy in developing countries especially is mainly by mass drug administration (MDA) approach. It is the means of combating helminthic infections such as schistosomiasis, ascariasis, Lymphatic filariasis, trichuriasis, onchocerciasis, and trachoma. Periodically, preventive treatment with anthelmintics is given to all at-risk people living in endemic areas in order to reduce the worm burden and hence decrease morbidity and improve the lives of affected populations. This is yielding significant benefits but needs a long-term commitment [83, 84].

The ultimate goal of infectious disease control, however, is to achieve total eradication. With smallpox having been eradicated, and a great wealth of lessons learned from previous epidemic events such as the West African Ebola crisis, there is optimism that eradication is a reality that must be pursued relentlessly.

8. Major Advances in Infectious Disease Control Efforts

The progress made over the past century in combating emerging infectious diseases came about as a result of engagement of several disciplines, namely, environmental studies, epidemiology, immunology, public health, social and cultural studies, pharmacology, medicine, molecular biology, chemistry, veterinary science, sociology, and anthropology among others [85–87]. Advances in basic science research and development of molecular technology and diagnostics have enhanced understanding of disease aetiology, pathogenesis, and molecular epidemiology, which provide basis for appropriate detection, prevention, and control measures as well as rational design of vaccine, by which some diseases have been successfully eliminated.

The development of the nucleic acid detection and genome sequencing technology in the nineteenth century has tremendously revolutionized infectious disease research, especially pathogenesis, diagnosis, and treatment and hence optimum patient care and management. A number of molecular assays have been developed for the detection, characterization, and quantitation of the ever-increasing number of infectious pathogens at a faster rate and with higher sensitivity and specificity as compared to traditional methods [2, 88]. From the initial stages of single pathogen detection, nucleic acid amplification methods today have been developed with a high-throughput capacity to generate a wealth of data on various types of pathogens (e.g., bacteria, parasites, and viruses) with specific disease markers (e.g., virulence, antibiotic resistance, and susceptibility factors) present in various types of specimen including blood, stool, swabs, urine, cerebrospinal fluid (CSF) samples, and respiratory secretions. Further, automation of nucleic acid detection technology provides “cutting-edge” platforms, the output of which ultimately greatly impacts patient management [89, 90] and also affords more efficient epidemiological and public health interventions.

Advances in molecular diagnostics and sequencing technology have played pivotal role in the control of many infectious diseases. In HIV disease treatment, for example, measurement of plasma HIV-1 viral load is an important technique for monitoring treatment efficacy [91]; while viral gene sequencing is a crucial method by means of which drug resistance development is monitored in HIV-infected persons on antiretroviral therapy (ART). These techniques have been tremendously instrumental in the current ART success story [92].

The acquisition of genomic and protein data has contributed to successful vaccine design and drug development against most of the infectious disease pathogens. A better understanding of known pathogens and discovery of new or previously unknown infectious diseases has been facilitated through genomic and proteomic studies. Elucidation of the pathogenesis of the malaria parasite Plasmodium falciparum and individual’s susceptibility or resistance to malaria contributed to the development of malaria vaccine (Mosquirix, the first against a parasitic infection in humans) [93]. Other achievements include the discovery of polio vaccine, anti-HIV drugs, and antimicrobials for various infectious agents like cancer-causing human papilloma virus, meningitis-causing pneumococci, and Haemophilus influenza type B; the recent Ebola vaccine represents landmark breakthroughs [12, 94].

Not only has advance in acquisition of genomic data contributed substantially to the development of vaccines and antimicrobials, but also it has important application in deciding and guiding successful treatment. Typical examples can be found in HIV antiretroviral therapy. Assay for the type of coreceptor usage by a patient’s predominant virus population, whether CCR5- or CXCR4-tropic virus, is necessary before using the antiretroviral drug Maraviroc, which is a CCR5 coreceptor antagonist [95]; the nucleoside reverse transcriptase inhibitor d, Abacavir (ABC), is associated with drug hypersensitivity reactions. This drug may lead to high rates of myocardial infarction in patients who are positive for human leukocyte antigen (HLA) type B5701 allele. Safe use of Abacavir therefore requires testing patients genetic data for HLA B5701 allele [96].

Besides pathogen and human factors, notable milestones have been achieved in the global sociopolitical front in addressing infectious disease problems. Since the dawn of this century concerted efforts have been made globally by global organizations, governments, foundations, and partner bodies towards infectious disease control. The United Nation’s decision to “combat HIV/AIDS, malaria, and other related diseases” as part, sixth goal, of the eight MDGs has led to transforming HIV from deadly to chronic, manageable disease. Other global initiatives in the fight against HIV include the United Nations–supported Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM), the World Health Organization (WHO) “3 by 5” initiative, and the US President’s Emergency Program for AIDS Relief (PEPFAR) [97, 98]. NTDs have also received impressive and unprecedented global attention, with heavy financial and research commitments by major institutions and organizations (see section on public health response) [76, 99].

In real terms, the outcome of advances in response to infectious disease threats reflects in marked progress in infectious disease control and human health protection. The discovery of vaccine about two hundred years ago by Edward Jenner (the English physician) has made it possible to prevent approximately 9 million deaths each year globally through routine immunization [100, 101]. Some vaccine-preventable diseases that are at various levels towards eradication include polio, diphtheria, whooping cough, measles, neonatal tetanus, hepatitis B, and tuberculosis. Others are Rubella, Dracunculiasis (Guinea worm), Lymphatic filariasis (elephantiasis), onchocerciasis (river blindness), and Mumps [37, 51, 102].

WHO has planned to eliminate measles by the year 2020. Polio is currently seen in three countries, Afghanistan, Nigeria, and Pakistan, but efforts are underway for its complete eradication and, down from nearly 3.5 million cases in 1986, today there are just 126 cases of Guinea worm recorded globally [103]; Guinea worm disease could be the second human disease after smallpox to be eradicated.

9. The Challenge and the Way Forward

The persistent and unpredictable nature of infectious disease emergence represents a continual challenge. Despite significant advances, especially during the past 2 decades, IDs continue to kill several millions of people each year. New and more virulent pathogens continue to emerge and reemerge. Human, social, political, environmental, technological, microbial, and ecological factors impacting infectious disease upsurge continue to increase [104]. Successful approaches to combating emerging infectious diseases threats require consideration of potential challenges and devise means to address them.

9.1. Genetic Variation

Genetic changes in pathogenic microorganisms confer new phenotypic properties that adapt infectious agents to new or old hosts, which may be favoured by changing host and environmental conditions. This enhances infectious disease emergence and reemergence, often causing new pandemics. Influenza viruses are a classic example of emerging and reemerging infectious agents, by their ability to undergo multiple genetic changes and evolve in response to changing host and environmental conditions [2, 51, 65, 105]. The IDs emergence threat thus persists as long as pathogens continue to undergo genetic changes and human and environmental activities that favour pathogen adaptation to infection in humans continue. However, findings suggest that virulence of pathogenic microorganisms may be caused by factors other than genetic variation. In the 2013–2016 West Africa Ebola virus disease outbreak, for example, even though rapid genomic variation could be responsible for virulence and transmission rates, pathogenesis studies did not find significant association between change in the virus with the magnitude of the outbreak, suggesting factors extrinsic to the virus to be responsible [63]. This depicts the complex nature of factors that may lead to infectious disease emergence and the enormity of the infectious disease challenge. There is therefore no promise that advances in infectious disease detection and control strategies can successfully stop new diseases from appearing, as each new disease brings unique challenges. Besides, the fact that so far only one human infectious disease (smallpox) has been successfully eradicated and there are many more whose pathogenesis have yet to be understood suggests that elimination of a disease once it gains way into human population is a hard task that deserves all persistent efforts to terminate its persistence.

9.2. Antimicrobial Resistance

Another major problem arising from genetic changes is the development of resistance to drugs [106]. A typical example is seen in HIV. Besides drug-drug interactions and toxic side effects, drug resistance arising from drug pressure coupled with high rate of genomic variation (during viral replication) is a major obstacle in HIV antiretroviral therapy, leading to treatment failure and necessitating regimen switches [107, 108]. Current antiretroviral therapy therefore employs a combination of anti-HIV compounds from at least two classes or drug groups with different mechanisms of action against HIV replication. Combination ART is necessary to suppress plasma HIV viremia, restore immunologic function, and reduce likelihood of drug resistance development for favourable treatment outcomes [109]. The problem of emergence of drug resistant microbes and resistance to antimicrobial agents very well characterizes many bacterial infectious agents such as Escherichia coli, Pneumococcus, Neisseria gonorrhoeae, and Staphylococcus aureus. Many well known antibiotics no longer clear bacterial infections due to microbial resistance. Evolution of drug resistant pathogens thus necessitates continued development of new antiviral and antimicrobial products. As such for HIV alone there are currently at least 25 anti-HIV compounds licensed for the treatment of AIDS [110].

9.3. Surveillance

This nature of infectious disease challenge calls for constant surveillance and timely intervention. There is need to develop and effectively deploy vaccines and drugs where they are needed; there is also the need for necessary infrastructure and skilled personnel to support prompt diagnosis and a need for ongoing research to aid development of effective countermeasures. However, given the extensive distribution of pathogens [15, 67, 111], some of which are not yet known or fully described, and the variety of animal species involved, effective surveillance and control of IDs constitute a significant public health challenge, and also predicting zoonotic emerging disease events remains a subject requiring persistent scientific exploration.

9.4. The Way Forward

There are a number of lessons to be learned from past epidemics to help our appreciation of the unpredictable and devastating nature of IDs. Infectious disease-causing pathogens have demonstrated sufficiently their capacity to emerge and spread rapidly by any possible means across borders, exhibit high pathogenic potential, and evolve or mutate to resist drug attack. This calls for efficient armament at any time. This can be achieved through greater international cooperation; effective local, regional, and global networks for strong infectious disease surveillance and research collaboration to enable sharing of biological and study materials to enhance antimicrobial product development and vaccine trials; collaboration between animal and human health sciences to strengthen capacity for identification of microbial agents with epidemic potential so as to prevent their emergence; stable society; committed medical and political leadership; and resource prioritization. There is also the need to focus special attention on situations that promote disease emergence, especially human activities, that degrade environmental and alter ecological conditions, which increase animals contact with humans. These are vital for a meaningful pandemic preparedness.

10. Conclusion

Emerging and neglected infectious diseases are a real public health threat, and infectious disease outbreaks can have serious social, political, and economic effects. Much have been learned from previous outbreak events and far-reaching advances have been made since the landmark IOM report [11], which underscored the important concept of emerging infectious diseases. Pandemic preparedness however remains a major global challenge. A complex number of factors relating to human behaviour and activities, pathogen evolution, poverty, and changes in the environment as well as dynamic human interactions with animals have been found to contribute to infectious disease emergence and transmission. Aggressive research is warranted to unravel important characteristics of pathogens necessary for diagnostics, therapeutics, and vaccine development and possibly enable detection of those pathogens with the potential to cause epidemic. National and international organizations networking, effective interagency and international research collaborations, appropriate financial support of the public health infrastructure, and poverty reduction are very vital for addressing emerging and neglected infectious disease threats.

Competing Interests

The author declares that there is no conflict of interests regarding the publication of this paper.

References

World Health Organization, “Infections and infectious diseases: a manual for nurses and midwives in the WHO European Region,” http://www.euro.who.int/__data/assets/pdf_file/0013/102316/e79822.pdf.

M. Tibayrenc, Encyclopedia of Infectious Diseases: Modern Methodologies, John Wiley & Sons, 2007.

A. Ashley-Koch, Q. Yang, and R. S. Olney, “Sickle hemoglobin (Hb S) allele and sickle cell disease: a HuGE review,” American Journal of Epidemiology, vol. 151, no. 9, pp. 839–845, 2000.

National Institutes of Health (US) and BSC Study, Understanding Emerging and Re-emerging Infectious Diseases, National Institutes of Health (US), 2007.

M. J. Walker, T. C. Barnett, J. D. McArthur et al., “Disease manifestations and pathogenic mechanisms of group A Streptococcus,” Clinical Microbiology Reviews, vol. 27, no. 2, pp. 264–301, 2014.

V. R. Racaniello, “Emerging infectious diseases,” The Journal of Clinical Investigation, vol. 113, no. 6, pp. 796–798, 2004.

N. C. Barber and L. A. Stark, “Online resources for understanding outbreaks and infectious diseases,” CBE Life Sciences Education, vol. 14, no. 1, 2015.

D. M. Morens, G. K. Folkers, and A. S. Fauci, “Emerging infections: a perpetual challenge,” The Lancet Infectious Diseases, vol. 8, no. 11, pp. 710–719, 2008.

M. Vitoria, R. Granich, C. F. Gilks et al., “The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives,” American Journal of Clinical Pathology, vol. 131, no. 6, pp. 844–848, 2009.

D. Rifkind and G. Freeman, The Nobel Prize Winning Discoveries in Infectious Diseases, Academic Press, 2005.

Institute of Medicine, Emerging Infections: Microbial Threats to Health in the United States, National Academy Press, Washington, DC, USA, 1992.

D. M. Morens and A. S. Fauci, “Emerging infectious diseases in 2012: 20 years after the institute of medicine report,” mBio, vol. 3, no. 6, 2012.

J. Becker and M. Barry, Emerging and Reemerging Viral Infectious Diseases, Prepared as Part of an Education Project of the Global Health Education Consortium and Collaborating Partners, Yale University School of Medicine, New Haven, Conn, USA, 2009.

C. to R. the D. of D.G.E.I.S. and R. System, M.F.-U. Agency, and I. of Medicine: “Perspectives on the Department of Defense global emerging infections surveillance and response system: a program review” National Academies Press, 2001.

World Health Organization, “WHO | Global infectious disease surveillance,” http://www.who.int/mediacentre/factsheets/fs200/en/.

F. L. Cohen and E. Larson, “Emerging infectious diseases: nursing responses,” Nursing Outlook, vol. 44, no. 4, pp. 164–168, 1996.

V. B. Carruthers, P. A. Cotter, and C. A. Kumamoto, “Microbial pathogenesis: mechanisms of infectious disease,” Cell Host and Microbe, vol. 2, no. 4, pp. 214–219, 2007.

A. Alcaïs, L. Abel, and J.-L. Casanova, “Human genetics of infectious diseases: between proof of principle and paradigm,” Journal of Clinical Investigation, vol. 119, no. 9, pp. 2506–2514, 2009.

J. Mouchet and P. Carnevale, “Impact of changes in the environment on vector-transmitted diseases,” Sante, vol. 7, no. 4, pp. 263–269, 1997.

C. Neiderud, “How urbanization affects the epidemiology of emerging infectious diseases,” Infection Ecology & Epidemiology, vol. 5, 2015.

M. X. Tong, A. Hansen, S. Hanson-Easey et al., “Infectious diseases, urbanization and climate change: challenges in future China,” International Journal of Environmental Research and Public Health, vol. 12, no. 9, pp. 11025–11036, 2015.

S. S. Morse, “Factors and determinants of disease emergence,” OIE Revue Scientifique et Technique, vol. 23, no. 2, pp. 443–451, 2004.

J. Utzinger and J. Keiser, “Urbanization and tropical health— then and now,” Annals of Tropical Medicine and Parasitology, vol. 100, no. 5-6, pp. 517–533, 2006.

B. K. Defo, “Demographic, epidemiological, and health transitions: are they relevant to population health patterns in Africa?” Global Health Action, vol. 7, 2014.

M. Gayer, D. Legros, P. Formenty, and M. A. Connolly, “Conflict and emerging infectious diseases,” Emerging Infectious Diseases, vol. 13, no. 11, pp. 1625–1631, 2007.

F. R. Lashley, “Emerging infectious disease: vulnerabilities, contributing factors and approaches,” Expert Review of Anti-Infective Therapy, vol. 2, no. 2, pp. 299–316, 2004.

A. M. Marty, R. M. Conran, and M. G. Kortepeter, “Recent challenges in infectious diseases: biological pathogens as weapons and emerging endemic threats,” Clinics in Laboratory Medicine, vol. 21, no. 3, pp. 411–420, 2001.

Centers for Disease Control and Prevention, “Outbreaks chronology: Ebola virus disease—Ebola hemorrhagic fever—CDC,” http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html.

C. Dye, “After 2015: Infectious diseases in a new era of health and development,” Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 369, no. 1645, 2014.

World Health Organization, “WHO/The top 10 causes of death,” http://www.who.int/mediacentre/factsheets/fs310/en/index2.html.

A. S. Fauci, N. A. Touchette, and G. K. Folkers, “Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious Diseases,” Emerging Infectious Diseases, vol. 11, no. 4, pp. 519–525, 2005.

Z. A. Bhutta, J. Sommerfeld, Z. S. Lassi, R. A. Salam, and J. K. Das, “Global burden, distribution, and interventions for infectious diseases of poverty,” Infectious Diseases of Poverty, vol. 3, no. 1, article 21, 2014.

J. N. Hays, Epidemics and Pandemics: Their Impacts on Human History, ABC-CLIO, Santa Barbara, Calif, USA, 2005.

“Native Americans and the smallpox epidemic-archiving early America,” http://www.varsitytutors.com/earlyamerica/early-america-review/volume-11/native-americans-smallpox.

World Health Organization, “WHO—Smallpox,” http://www.who.int/csr/disease/smallpox/en/.

W. A. Orenstein, A. R. Hinman, and M. J. Papania, “Evolution of measles elimination strategies in the United States,” Journal of Infectious Diseases, vol. 189, no. 1, pp. S17–S22, 2004.

J. P. Baker, “The first measles vaccine,” Pediatrics, vol. 128, no. 3, pp. 435–437, 2011.

World Health Organization, “WHO—Measles,” http://www.who.int/mediacentre/factsheets/fs286/en/.

“The 1918 influenza pandemic,” https://virus.stanford.edu/uda/.

World Health Organization, “WHO—HIV/AIDS,” http://www.who.int/mediacentre/factsheets/fs360/en/.

G. D. Shanks and J. F. Brundage, “Pathogenic responses among young adults during the 1918 influenza pandemic,” Emerging Infectious Diseases, vol. 18, no. 2, pp. 201–207, 2012.

“MERS coronavirus: diagnostics, epidemiology and transmission/Virology Journal/Full Text,” https://virologyj.biomedcentral.com/articles/10.1186/s12985-015-0439-5.

C. J. Peters and J. W. LeDuc, “An introduction to Ebola: the virus and the disease,” Journal of Infectious Diseases, vol. 179, no. 1, pp. ix–xvi, 1999.

P. J. Hotez, M. Alvarado, M.-G. Basáñez et al., “The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases,” PLoS Neglected Tropical Diseases, vol. 8, no. 7, Article ID e2865, 2014.

M. G. Weiss, “Stigma and the social burden of neglected tropical diseases,” PLoS Neglected Tropical Diseases, vol. 2, no. 5, article e237, 2008.

G. C. Kombe and D. M. Darrow, “Revisiting emerging infectious diseases: the unfinished agenda,” Journal of Community Health, vol. 26, no. 2, pp. 113–122, 2001.

K. Deribe, K. Meribo, T. Gebre et al., “The burden of neglected tropical diseases in Ethiopia, and opportunities for integrated control and elimination,” Parasites & Vectors, vol. 5, no. 1, article no. 240, 2012.

J. Norris, C. Adelman, Y. Spantchak, and K. Marano, “Social and economic impact review on neglected tropical diseases,” Economic Policy/Briefing Paper, Hudson Institute, Washington, DC, USA, 2012.

K. B. Chua and D. J. Gubler, “Perspectives of public health laboratories in emerging infectious diseases,” Emerging Microbes and Infections, vol. 2, article no. e37, 2013.

J. C. Semenza, E. Lindgren, L. Balkanyi et al., “Determinants and drivers of infectious disease threat events in Europe,” Emerging Infectious Diseases, vol. 22, no. 4, pp. 581–589, 2016.

“Globalization and infectious diseases: a review of the linkages,” http://www.who.int/tdr/publications/documents/seb_topic3.pdf.

A. T. Pavia, “Germs on a plane: aircraft, international travel, and the global spread of disease,” Journal of Infectious Diseases, vol. 195, no. 5, pp. 621–622, 2007.

M. O. Nanyingi, P. Munyua, S. G. Kiama et al., “A systematic review of Rift Valley Fever epidemiology 1931–2014,” Infection Ecology & Epidemiology, vol. 5, Article ID 28024, 2015.

S. S. Morse, J. A. K. Mazet, M. Woolhouse et al., “Prediction and prevention of the next pandemic zoonosis,” The Lancet, vol. 380, no. 9857, pp. 1956–1965, 2012.

A. Tadin, R. Tokarz, A. Markotic et al., “Molecular survey of zoonotic agents in rodents and other small mammals in Croatia,” American Journal of Tropical Medicine and Hygiene, vol. 94, no. 2, pp. 466–473, 2016.

B. A. Han, A. M. Kramer, and J. M. Drake, “Global patterns of zoonotic disease in mammals,” Trends in Parasitology, vol. 32, no. 7, pp. 565–577, 2016.

A. M. Kilpatrick and S. E. Randolph, “Drivers, dynamics, and control of emerging vector-borne zoonotic diseases,” The Lancet, vol. 380, no. 9857, pp. 1946–1955, 2012.

K. H. Mayer and C. Beyrer, “HIV epidemiology update and transmission factors: risks and risk contexts—16th International AIDS Conference Epidemiology Plenary,” Clinical Infectious Diseases, vol. 44, no. 7, pp. 981–987, 2007.

J. R. Spengler, E. D. Ervin, J. S. Towner, P. E. Rollin, and S. T. Nichol, “Perspectives on west africa ebola virus disease outbreak, 2013–2016,” Emerging Infectious Diseases, vol. 22, no. 6, p. 956, 2016.

World Health Organization, “Ebola Situation Report-2 March 2016/Ebola,” http://apps.who.int/ebola/current-situation/ebola-situation-report-2-march-2016.

World Health Organization, “WHO—Ebola virus disease,” http://www.who.int/mediacentre/factsheets/fs103/en/.

A. Goba, S. H. Khan, M. Fonnie et al., “An Outbreak of Ebola virus disease in the Lassa fever zone,” Journal of Infectious Diseases, vol. 214, supplement 3, pp. S110–S121, 2016.

H. V. Fineberg and M. E. Wilson, “Emerging infectious diseases,” IRGC Report, 2010.

Emerging Infectious Diseases—Beginning of the 21st Century, http://www.medscape.com/viewarticle/528306.

“Blueprint for R&D preparedness and response to public health emergencies due to highly infectious pathogens: meeting-report-prioritization.pdf,” http://www.who.int/csr/research-and-development/meeting-report-prioritization.pdf.

A. Merianos, “Surveillance and response to disease emergence,” Current Topics in Microbiology and Immunology, vol. 315, pp. 477–509, 2007.

World Health Organization, “WHO/WHO publishes list of top emerging diseases likely to cause major epidemics,” http://www.who.int/medicines/ebola-treatment/WHO-list-of-top-emerging-diseases/en/.

World Health Organization, “WHO/Zika virus,” http://www.who.int/mediacentre/factsheets/zika/en/.

World Health Organization, “WHO—HIV/AIDS, TB, Malaria and Neglected Tropical Diseases (HTM),” http://www.who.int/about/structure/organigram/htm/en/.

K. L. Russell, J. Rubenstein, R. L. Burke et al., “The global emerging infection surveillance and response system (GEIS), a U.S. government tool for improved global biosurveillance: a review of 2009,” BMC Public Health, vol. 11, supplement 2, article S2, 2011.

World Health Organization, “WPRO—Responding to emerging infectious disease threats,” http://www.wpro.who.int/mediacentre/releases/2013/20131024apsed/en/.

C. S. Wiysonge, Z. Waggie, A. Hawkridge et al., “Advocating for efforts to protect African children, families, and communities from the threat of infectious diseases: report of the first international African vaccinology conference,” Pan African Medical Journal, vol. 23, 2016.

World Health Organization, “WHO | World Health Assembly adopts resolution on neglected tropical diseases,” http://www.who.int/neglected_diseases/WHA_66_seventh_day_resolution_adopted/en/.

Bill and Melinda Gates Foundation, “Gates Foundation commits nearly 70 million to help fight neglected tropical diseases—Bill & Melinda Gates Foundation,” http://www.gatesfoundation.org/Media-Center/Press-Releases/2006/09/$70-Million-to-Help-Fight-Neglected-Tropical-Diseases.

World Health Organization, “Who | the global network for neglected tropical diseases control (GNNTDC),” http://www.who.int/neglected_diseases/GNNTDC/en/.

Bill and Melinda Gates Foundation, “Private and public partners unite to combat 10 neglected tropical diseases by 2020,” http://www.gatesfoundation.org/media-center/press-releases/2012/01/private-and-public-partners-unite-to-combat-10-neglected-tropical-diseases-by-2020.

“Control of Neglected Tropical Diseases—NEJM,” http://www.nejm.org/doi/full/10.1056/NEJMra064142#t=article.

Bill and Melinda Gates Foundation, “Neglected tropical diseases,” http://www.gatesfoundation.org/What-We-Do/Global-Health/Neglected-Tropical-Diseases.

“London_Declaration_NTDs.pdf,” http://www.who.int/neglected_diseases/London_Declaration_NTDs.pdf.

World Health Organization, “Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation: executive summary,” 2012, http://apps.who.int/iris/handle/10665/70809.

Y. Zhang, C. MacArthur, L. Mubila, and S. Baker, “Control of neglected tropical diseases needs a long-term commitment,” BMC Medicine, vol. 8, article no. 67, 2010.

M. J. Bockarie, L. A. Kelly-Hope, M. Rebollo, and D. H. Molyneux, “Preventive chemotherapy as a strategy for elimination of neglected tropical parasitic diseases: endgame challenges,” Philosophical Transactions of the Royal Society of London. B. Biological sciences, vol. 368, no. 1623, 2013.

S. Kappagoda and J. P. A. Ioannidis, “Prevention and control of neglected tropical diseases: overview of randomized trials, systematic reviews and meta-analyses,” Bulletin of the World Health Organization, vol. 92, no. 5, pp. 356–366, 2014.

C. Hanson, A. Weaver, K. L. Zoerhoff et al., “Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: identifying best practices to roll out programs at national scale,” American Journal of Tropical Medicine and Hygiene, vol. 86, no. 3, pp. 508–513, 2012.

“Quantitative analysis of strategies to achieve the 2020 goals for neglected tropical diseases: where are we now?” https://www.biomedcentral.com/collections/ntdmodels2015.

K. L. Muldrew, “Molecular diagnostics of infectious diseases,” Current Opinion in Pediatrics, vol. 21, no. 1, pp. 102–111, 2009.

M. Rweyemamu, D. Kambarage, E. Karimuribo et al., “Development of a One Health National Capacity in Africa: the Southern African Centre for Infectious Disease Surveillance (SACIDS) One Health Virtual Centre Model,” Current Topics Microbiology Immunology, vol. 366, pp. 73–91, 2013.

A. M. Caliendo, D. N. Gilbert, C. C. Ginocchio et al., “Tests, better care: improved diagnostics for infectious diseases,” Clinical Infectious Diseases, vol. 57, supplement 3, pp. S139–S170, 2013.

World Health Organization, “WHO—7.3 Monitoring response to ART and the diagnosis of treatment failure,” http://www.who.int/hiv/pub/guidelines/arv2013/art/artmonitoring/en/index3.html.

A. Calmy, N. Ford, B. Hirschel et al., “HIV viral load monitoring in resource-limited regions: optional or necessary?” Clinical Infectious Diseases, vol. 44, no. 1, pp. 128–134, 2007.

World Health Organization, “WHO—HIV drug resistance: publications,” http://www.who.int/hiv/pub/drugresistance/en/.

S. Bertagnolio, C. F. Perno, S. Vella, and D. Pillay, “The impact of HIV drug resistance on the selection of first- and second-line ART in resource-limited settings,” Journal of Infectious Diseases, vol. 207, no. 2, pp. S45–S48, 2013.

B. B. C. News, “Malaria vaccine gets ‘green light’,” http://www.bbc.com/news/health-33641939.

N. D. Goswami, C. D. Pfeiffer, J. R. Horton, K. Chiswell, A. Tasneem, and E. L. Tsalik, “The state of infectious diseases clinical trials: a systematic review of clinicaltrials.gov,” PLoS ONE, vol. 8, no. 10, Article ID e77086, 2013.

“Maraviroc: a Coreceptor CCR5 antagonist for management of HIV infection,” http://www.medscape.com/viewarticle/705842_1.

M. Janardhanan, V. M. B. Amberkar, S. Vidyasagar, K. M. Kumari, and S. N. Holla, “Hypersensitivity reaction associated with abacavir therapy in an Indian HIV patient—a case report,” Journal of Clinical and Diagnostic Research, vol. 8, no. 9, pp. HD01–HD02, 2014.

World Health Organization, “WHO | about the 3 by 5 initiative,” http://www.who.int/3by5/about/initiative/en/.

V. D. Lima, R. Granich, P. Phillips, B. Williams, and J. S. G. Montaner, “Potential impact of the us president's emergency plan for AIDS relief on the tuberculosis/HIV coepidemic in selected sub-Saharan African countries,” Journal of Infectious Diseases, vol. 208, no. 12, pp. 2075–2084, 2013.

World Health Organization, “Investing to overcome the global impact of neglected tropical diseases—Third WHO report on neglected tropical diseases,” http://apps.who.int/iris/bitstream/10665/152781/1/9789241564861_eng.pdf?ua=1.

PFIZER, “The value of vaccines in disease prevention,” https://www.pfizer.com/files/health/VOMPaper_Vaccines_R7.pdf.

ThinkProgress, “Vaccines have almost totally eliminated these 13 infectious diseases in the U.S.—thinkprogress,” https://thinkprogress.org/vaccines-have-almost-totally-eliminated-these-13-infectious-diseases-in-the-u-s-653d4a8f930e.

Institute of Medicine (U.S.) and Forum on Microbial Threats, Global Infectious Disease Surveillance and Detection Assessing the Challenges—Finding Solutions: Workshop Summary, National Academies Press, Washington, DC, USA, 2007.

World Health Organization, “WHO—Dracunculiasis (guinea-worm disease),” http://www.who.int/mediacentre/factsheets/fs359/en/.

S. Zyga and M. Zografakis-Sfakianakis, “Emerging and re-emerging infectious diseases: a potential pandemic threat,” Health Science Journal, vol. 5, no. 3, pp. 159–168, 2011.

Vaccines Today, “Influenza pandemics—a brief history,” http://www.vaccinestoday.eu/diseases/influenza-pandemics-a-brief-history/.

W. G. Meyer, J. A. Pavlin, D. Hospenthal et al., “Antimicrobial resistance surveillance in the AFHSC-GEIS network,” BMC Public Health, vol. 11, no. 2, article S8, 2011.

E. Y. Klein, “Antimalarial drug resistance: a review of the biology and strategies to delay emergence and spread,” International Journal of Antimicrobial Agents, vol. 41, no. 4, pp. 311–317, 2013.

A. S. Fauci and D. M. Morens, “The perpetual challenge of infectious diseases,” New England Journal of Medicine, vol. 366, no. 5, pp. 454–461, 2012.

E. De Clercq, “Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV,” International Journal of Antimicrobial Agents, vol. 33, no. 4, pp. 307–320, 2009.

Institute of Medicine (U.S.) forum on microbial threats, Global Infectious Disease Surveillance and Detection: Assessing the Challenges—Finding the Solutions, National Academies Press, Washington, DC, USA, 2007.

J. Adams, K. A. Gurney, and D. Pendlebury, Global Research Report on Neglected Tropical Diseases, Thomson Reuters, 2012.